TH9507

CAS: 218949-48-5
Molecular wt: 5136
Compound class: Synthetic GHRH analog peptide

Don’t see your product’s COA?

Search our full archive of third-party verified Certificates of Analysis to pull the exact batch you received.

TH9507

TH9507 (tesamorelin, CAS 218949-48-5) is a 44-amino-acid GRF analogue retaining the full-length sequence rather than the GRF(1-29) fragment. Published canine pharmacokinetics cover intravenous, subcutaneous and pulmonary routes. Purity and identity are stated on the batch-specific COA.

TH9507 is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms and Conditions prior to ordering.

Description

TH9507 (Tesamorelin) Research Standard

TH9507, also indexed as tesamorelin (CAS 218949-48-5), is a 44-amino-acid peptide analogue of natural human growth hormone releasing factor. Unlike the GRF(1-29) analogues it retains the full-length 44-residue sequence rather than the shortened active fragment, which makes it the natural comparator when a study needs to ask whether the truncation matters.^[1]

Mechanism of Action & Research Context

The molecular target is the growth hormone-releasing hormone receptor (GHRH-R), a class II GPCR on pituitary somatotrophs — a different receptor from the GHS-R1a targeted by the ghrelin-mimetic secretagogues.

The receptor. GHRH-R is a class II G-protein-coupled receptor required for normal growth hormone synthesis and release, and for normal growth and proliferation of pituitary somatotrophs. Mutations in mouse and human are associated with GH deficiency, short stature and pituitary hypoplasia. Alternative mRNA splicing produces variants proposed to act as dominant-negative inhibitors of the wild-type receptor.^[3]
Full-length rather than truncated. Sermorelin and the CJC analogues are built on GRF(1-29). TH9507 keeps all 44 residues, so a panel containing both lets the contribution of residues 30–44 be tested directly rather than assumed irrelevant.
DPP-IV is the limiting factor. GRF(1-29)NH₂ is degraded mainly by dipeptidyl peptidase IV, which clips the N-terminal dipeptide to leave inactive GRF(3-29)NH₂. Analogues designed to resist plasma DPP-IV are markedly more stable, and that resistance carries across compartments — a DPP-IV-resistant analogue was far more stable than the parent in intestinal enterocytes as well as plasma.^[2]
Characterised canine pharmacokinetics. In beagle dogs, terminal half-life was 39 minutes after intratracheal dry-powder insufflation and 26 minutes after subcutaneous injection, with no significant difference between routes. Mean residence time was longer intratracheally (74 against 52 minutes). Bioavailability by the inhaled route was 41% relative to subcutaneous, with absolute bioavailability estimated at 13%.^[1]
A route-comparison dataset. Few peptides in this catalogue have published side-by-side intravenous, subcutaneous and pulmonary data in the same species. That makes TH9507 useful for delivery and formulation work well beyond its own pharmacology.^[1]

Research Applications

Primary fields of in vitro and preclinical laboratory investigation include:

Delivery-route and formulation studies, including dry-powder insufflation against subcutaneous and intravenous dosing.^[1]
Pharmacokinetic modelling using published half-life, MRT and bioavailability values.^[1]
Structure-activity comparison of full-length GRF against GRF(1-29) analogues.
Receptor pharmacology at GHRH-R.^[3]

Analytical Documentation

Purity and identity vary by manufacturing lot. Kimera Chems does not publish a single fixed purity figure for this item; refer to the batch-specific Certificate of Analysis (COA) issued for the lot received, which reflects third-party analytical testing for that lot.

References

Jansen M, Darby I, Abribat T, Dubreuil P, Ferdinandi ES, Hardy JG. Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog. Int J Pharm. 2004;276(1–2):75–81. doi:10.1016/j.ijpharm.2004.02.012
Bai JP, Chang LL. The involvement of dipeptidyl peptidase IV in brush-border degradation of GRF(1-29)NH2 by intestinal mucosal cells. J Pharm Pharmacol. 1995;47(8):698–701. doi:10.1111/j.2042-7158.1995.tb05863.x
Gaylinn BD. Growth hormone releasing hormone receptor. Recept Channels. 2002;8(3–4):155–162. PMID: 12529933.

Related Research Compounds

Compound Class	Synthetic GHRH analog peptide
CAS Number	218949-48-5
Other Names	Egrifta, TH9507, 804475-66-9, TH 9507
IUPAC Name	(4S)-4-[[2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2-[[(E)-hex-3-enoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-3-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-5-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
Molecular Formula	C₂₂₁H₃₆₆N₇₂O₆₇S
Molecular Weight	5136
Lyophilised Vial Concentration	10mg, 5mg

5-Amino-1MQ

Login to view price
5-Amino/MIC

Login to view price
ACE-031

Login to view price
AOD-9604

Login to view price

Research Use Only
All products supplied by Kimera Chems LLC are intended strictly for laboratory research use. They are not drugs, dietary supplements, food, cosmetics, or veterinary products, and are not for human or animal consumption.

Regulatory Status
Kimera Chems LLC is a chemical supplier. Kimera Chems is not a compounding pharmacy or chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act, and is not an outsourcing facility as defined under Section 503B of that Act.

Intended Use and Handling
The products we offer are not intended for human use. They are intended for in-vitro and pre-clinical research purposes only. The customer acknowledges that risks exist in the handling, use, and distribution of these products, and certifies that it has the proper equipment, facilities, and personnel to manage those risks, and knowingly accepts them. These chemicals are not intended to be used, and should not be used, in inappropriate applications — including, without limitation, as food additives, drugs, cosmetics, or household chemicals, or in any application outside of in-vitro laboratory research, pre-clinical research, or laboratory chemical synthesis and materials testing.

Customer Responsibility
By purchasing these products, the customer agrees to the above. In the event the customer uses, or causes others to use, these products outside of these restrictions, the customer accepts all risk of doing so, absolves Kimera Chems of any responsibility for such actions, and agrees to indemnify and hold Kimera Chems harmless against any third-party claims arising from them.